WASHINGTON / RankWire.AI / – A groundbreaking study published in the journal Science has revealed a rare inherited genetic mutation that can elevate an individual’s risk of developing lung cancer by approximately 25 times overall and by about 60 times among non-smokers, according to researchers. This research, carried out by scientists at the Dana-Farber Cancer Institute in collaboration with the 23andMe Research Institute, utilized de-identified genetic information from over 3.3 million individuals. The germline variant known as EGFR T790M was identified by the team as one of the strongest inherited risk factors for lung cancer discovered to date.
This mutation takes place in the epidermal growth factor receptor gene, which is responsible for controlling cell growth and division within lung tissue. While somatic EGFR mutations, acquired during a person’s lifetime, are recognized as key drivers of non-small cell lung cancer, the T790M germline mutation is inherited from birth and is present in every cell. Data from the National Cancer Institute indicates that this mutation affects roughly 1 in every 15,850 individuals in the United States. Dr. Jaclyn LoPiccolo, the principal author of the study, pointed out that carriers of the variant have about a 62-fold increased risk of lung cancer among never-smokers, compared to roughly 11 times in those with a history of smoking.
Genetic lineage analysis uncovered a higher concentration of the EGFR T790M mutation in populations across Southern Appalachia, notably in Tennessee and Alabama. Evolutionary geneticists traced the mutation back to British and Irish settlers who migrated to North America during the colonial period, with its prevalence increasing after a genetic bottleneck approximately 200 years ago. Senior study author Dr. Pasi A. Jänne highlighted that, although current lung cancer screening mostly targets tobacco use, recognizing potent genetic risk factors offers new possibilities for focused low-dose computed tomography screening in individuals without a history of smoking.
Genetic Variant Could Amplify Lung Cancer Risk Up to 60 Times in Non-Smokers
Supported by the National Institutes of Health through preclinical and clinical research, scientists confirmed that this mutation shows a strong specific connection with lung cancer, with no significant links to 17 other prevalent cancers evaluated in the dataset. Oncologists pointed out that, despite tobacco exposure remaining the primary cause of lung cancer overall, cases among non-smokers are becoming a significant global health concern. Companies like AstraZeneca are actively developing targeted tyrosine kinase inhibitors such as Tagrisso to combat EGFR-mutated lung cancers as tumors progress.
Dr. Alexander Gusev, co-senior author of the study, remarked that the findings demonstrate how a single inherited point mutation can have an extraordinarily strong impact on disease susceptibility. Medical professionals advise those with multiple family members affected by lung cancer, unexplained multifocal lung nodules, or roots tracing back to Southern Appalachia to seek guidance from genetic counselors. The researchers stressed that carrying the mutation does not necessarily lead to lung cancer, as environmental factors and secondary genetic changes also influence the risk of malignant transformation over a lifetime.
Multi-Research Center Study Analyzes Genetic Data from Over Three Million Individuals
The consortium plans to broaden observational studies through the ongoing INHERIT Study, aiming to investigate additional inherited EGFR variants among diverse racial groups. Long-term analysis will focus on pinpointing specific environmental triggers and secondary genetic alterations that determine why some carriers develop tumors while others remain asymptomatic.
Findings on population genetics, relative risk assessments, and screening protocols are accessible through peer-reviewed medical repositories and institutional release portals. Clinical researchers will showcase updated biomarker data at upcoming international oncology conferences to guide future screening practices.